These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 14994225)
1. DNA histogram analysis for node-negative breast cancer. Bagwell CB Cytometry A; 2004 Mar; 58(1):76-8. PubMed ID: 14994225 [No Abstract] [Full Text] [Related]
2. Flow cytometric analysis of DNA ploidy in primary, metastatic and recurrent breast cancers. Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y Oncol Rep; 2002; 9(4):793-9. PubMed ID: 12066211 [TBL] [Abstract][Full Text] [Related]
3. [Microscopic DNA cytophotometry of axillary lymph node metastasis in mammary carcinomas]. Tawfik M; Börner P; Krause PH Verh Dtsch Ges Pathol; 1990; 74():258-61. PubMed ID: 1708597 [TBL] [Abstract][Full Text] [Related]
4. [Nuclear DNA content in breast cancer--relation between ploidy and lymph node metastasis]. Nishi T; Okajima K; Fujiwara A; Yasuda M; Yamada S; Taguchi T; Sekimoto T Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):103-7. PubMed ID: 3701162 [No Abstract] [Full Text] [Related]
5. DNA and cell cycle analysis as prognostic indicators in breast tumors revisited. Bagwell CB; Clark GM; Spyratos F; Chassevent A; Bendahl PO; Stål O; Killander D; Jourdan ML; Romain S; Hunsberger B; Wright S; Baldetorp B Clin Lab Med; 2001 Dec; 21(4):875-95, x. PubMed ID: 11770293 [TBL] [Abstract][Full Text] [Related]
6. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer]. Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the correlations of cell proliferation activity with lymphatic and vascular invasion and prognosis in gastric carcinoma]. Wu YF; Xu HM; Chen JQ Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):492-5. PubMed ID: 16188150 [TBL] [Abstract][Full Text] [Related]
8. Flow cytometric S-phase fraction measurement in breast carcinoma: Influence of software and histogram resolution. Jourdan ML; Ferrero-Poüs M; Spyratos F; Romain S; Martin PM; Chassevent A Cytometry; 2002 Jun; 48(2):66-70. PubMed ID: 12116366 [TBL] [Abstract][Full Text] [Related]
9. Second thoughts on sentinel lymph node biopsy in node-negative breast cancer. Kuijt GP; Roumen RM Br J Surg; 2008 Mar; 95(3):310-1. PubMed ID: 17952887 [No Abstract] [Full Text] [Related]
10. Predictors of non-sentinel lymph node metastasis in breast cancer patients. Goyal A; Douglas-Jones A; Newcombe RG; Mansel RE; Eur J Cancer; 2004 Jul; 40(11):1731-7. PubMed ID: 15251163 [TBL] [Abstract][Full Text] [Related]
11. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485 [TBL] [Abstract][Full Text] [Related]
12. Quality control in image cytometry: DNA ploidy. Bacus JW; Bacus JV J Cell Biochem Suppl; 1994; 19():153-64. PubMed ID: 7823587 [TBL] [Abstract][Full Text] [Related]
13. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661 [TBL] [Abstract][Full Text] [Related]
14. Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration. van der Ploeg IM; Kroon BB; Antonini N; Valdés Olmos RA; Rutgers EJ; Nieweg OE Ann Surg Oncol; 2008 Apr; 15(4):1025-31. PubMed ID: 18219534 [TBL] [Abstract][Full Text] [Related]
15. DNA flow cytometry measurements and their clinical relevance in node-negative breast cancer patients. Dressler LG Recent Results Cancer Res; 1993; 127():61-9. PubMed ID: 8502831 [No Abstract] [Full Text] [Related]
16. Are DNA flow cytometry measurements providing useful information in the management of the node-negative breast cancer patient? Dressler LG Cancer Invest; 1992; 10(5):477-86. PubMed ID: 1393694 [TBL] [Abstract][Full Text] [Related]
17. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432 [TBL] [Abstract][Full Text] [Related]
19. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference. Hedley DW; Clark GM; Cornelisse CJ; Killander D; Kute T; Merkel D Cytometry; 1993; 14(5):482-5. PubMed ID: 8354119 [No Abstract] [Full Text] [Related]
20. Ploidy and kinetics: comparative study with DNA flow cytometry and AgNOR protein quantification with image analysis. Grigolato PG; Tebaldi P; Cadei M; Alpi F; Lucchini K Eur J Histochem; 1997; 41 Suppl 2():131-2. PubMed ID: 9859816 [No Abstract] [Full Text] [Related] [Next] [New Search]